ClinicalTrials.gg
RecruitingNCT06874322Updated Sep 4, 2026

Voiceitt for People With Impairments in Speech

An interventional study of Voiceitt in Speech Impairment and Speech Disorder, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
13 Years and older
Sex
All
01

Study summary

The primary objective of this pilot study is to evaluate the feasibility and preliminary effectiveness of the Voiceitt app in improving communication for individuals with speech impairments due to conditions such as cerebral palsy (CP), stroke, Amyotrophic Lateral Sclerosis (ALS), or Parkinson's disease.

Read the detailed description

Conditions like CP, ALS, Stroke or Parkinson's disease, etc., cause communication impairment. There are few augmentative communication options that allow people with these impairments to communicate effectively.

Voiceitt is an app that is designed to assist people with speech impairments by using a voice recognition and dictation tool that adapts to users' unique, non-standard speech patterns. However, its effectiveness in clinical populations has not been established. This study is bridging the gap in evaluating the preliminary effectiveness and feasibility of Voiceitt app in improving communication among people with mild to moderate speech impairments.

02

Conditions studied

  • Speech Impairment
  • Speech Disorder

Keywords

  • Speech Impairment
  • voice recognition tool
  • dictation tool
  • voice recognition app
  • dictation app
  • voiceitt app
  • speech disabilities
  • dysarthria
  • moderate dysarthria
03

In context

Speech Disorders

77 studies on the registry are indexed under Speech Disorders; 20 are open to participants now.

This study's planned enrollment of 20 is below the median of 38 across 54 interventional studies indexed under Speech Disorders.

Browse Speech Disorders studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 13 or older
  • moderately severe speech dysarthria due to conditions such as CP, stroke, ALS or Parkinson's Disease, etc.
  • Ability to understand and follow instructions for using the Voiceitt app.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairments that prevent the understanding of the Voiceitt app and required training.
  • Patients who have additional speech impairments other than dysarthria, such as significant aphasia or verbal apraxia.
  • Severe physical impairments that prevent interaction with the app.
  • Non-English speakers.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Voiceitt

    Participants will use Voiceitt App. Voiceitt is a voice recognition and dictation tool that adapts to users' unique, non-standard speech patterns. It integrates with mainstream devices and platforms to enable communication, accessibility, and independence for people with speech disabilities. https://www.voiceitt.com/

    Other: Voiceitt

Interventions

  • OtherVoiceitt

    Participants will use Voiceitt App

06

What researchers measure

Primary outcomes

  1. Change in Communication Abilities as measured by SIR

    Change in Communication Abilities as measured by Speech Intelligibility Rating (SIR) that quantifies clarity of speech. The rating ranges from 1-5. low rating means speech is unintelligible, and highest rating means speech is intelligible to all listeners. Change in SIR is measured by administering SIR at 3 different time points, at baseline, and two times after intervention.

    Time frame: Baseline (Day 1), 5-6 months, and 7-8 months

  2. Change in Communication Abilities as measured by Communication Effectiveness Index (CETI)

    Change in Communication Abilities as measured by Communication Effectiveness Index (CETI) that measures perceived effectiveness of communication in daily activities. CETI is a 16 item questionnaire. Each item is scored from 1-100. The final score of CETI is the averaged score across the 16 items, and ranges from 1-100. A high score indicates good performance in functional communication and a low score, poor performance. Change in CETI is measured by administering CETI at 3 different time points, at baseline, and two times after intervention.

    Time frame: Baseline (day 1), 5-6 months, and 7-8 months

Secondary outcomes

  1. User Satisfaction

    User satisfaction is assessed through surveys and interviews focusing on ease of use, satisfaction with the app, and perceived changes. The survey uses Likert-type scale where users choose the answer option that represent their assessment of the app on several usability questions. An example of the question-and-answer choices is "How easy was it to set up the Voiceitt app? Very easy, Easy, Neutral, Difficult, Very difficult." Reported data will be a combination of frequency of participants choosing favorable and unfavorable answer choices, and a qualitative analysis based on participants' responses to the survey and interview.

    Time frame: 7-8 months

  2. Change in Communication-Related Frustration

    Self-reported change in frustration levels during communication.

    Time frame: 7-8 months

  3. Change in Participants' Accounts on Social Interaction Quality

    Through qualitative interviews, participants will be asked about how the app influenced their social interactions and participation in daily activities. This information will be reported qualitatively as themes using qualitative analysis.

    Time frame: 7-8 months

07

Study locations

1 of 1 sites recruiting
  • Center for Assistive Technology
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Katya Hill, PhD, CCC-SLP · Contactkhill@pitt.edu · 412-383-6659
    • Brad E Dicianno, MD · Contactdicianno@pitt.edu · (412) 648-6666
    • Brad E Dicianno, MD · Principal investigator
    • Katya Hill, PhD,CCC-SLP · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 35 non-industry interventional studies with no phase under Speech Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 38. This study's planned 30 months is close to that.

Counting every sponsor, half of 37 studies reached it within 28 months; a quarter within 17 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 13, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874322
Collaborators
Duquesne University
Responsible party
Brad Dicianno (Professor, University of Pittsburgh) — Principal investigator
First posted
Mar 13, 2025
Start date
Jun 25, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Brad E Dicianno, MD
Contact
dicianno@pitt.edu
(412) 648-6666
Zara Ambadar, Ph.D
Contact
ambadar@pitt.edu
4126086118
Brad E Dicianno, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion